Increased efficacy of gefitinib on cisplatin-resistant wild-type epidermal growth factor receptor non-small cell lung cancer cells

BACKGROUND: Gefitinib is a first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that has become first-line treatment for patients with mutant EGFR non-small cell lung cancer (NSCLC). Despite its anti-tumor activity, the benefit of gefitinib in patients with wild-typ...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Amin, Cao, Weiya, Liu, Xueke, Zhang, Yinci, Ma, Yongfang, Xu, Ruyue, Tang, Xiaolong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798197/
https://www.ncbi.nlm.nih.gov/pubmed/35117912
http://dx.doi.org/10.21037/tcr-20-1441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798197/
https://www.ncbi.nlm.nih.gov/pubmed/35117912
http://dx.doi.org/10.21037/tcr-20-1441

Ejemplares similares